Docosatetraenylethanolamide

Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a Ki value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system[1][2].

Product Specifications

CAS Number

[150314-35-5]

Product Name Alternative

DEA

UNSPSC

12352211

Hazard Statement

H225-H350

Target

Cannabinoid Receptor; Endogenous Metabolite

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease

Solubility

10 mM in DMSO

Smiles

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(NCCO)=O

Molecular Formula

C24H41NO2

Molecular Weight

375.59

Precautions

P210-P233-P240-P241-P242-P243-P280-P303+P361+P353-P370+P378-P403+P235-P405-P501

References & Citations

[1]Hanus L, et al. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem. 1993 Oct 1;36 (20) :3032-4.|[2]Pertwee R, et alcts of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur J Pharmacol. 1994 Jul 1;259 (2) :115-20.|[3]Walter L, et al. Astrocytes in culture produce anandamide and other acylethanolamides. J Biol Chem. 2002 Jun 7;277 (23) :20869-76.